Overview
Thyroid and adrenal diseases include a broad spectrum of benign and malignant endocrine disorders affecting hormonal regulation and metabolic balance.
Thyroid diseases
These include:
- Thyroid nodules (benign and malignant)
- Differentiated thyroid cancer (papillary, follicular)
- Medullary and anaplastic thyroid carcinoma
- Hyperthyroidism and hypothyroidism
Adrenal diseases
These include:
- Adrenal incidentalomas
- Adrenocortical adenoma and carcinoma
- Pheochromocytoma and paraganglioma
- Primary hyperaldosteronism (Conn’s syndrome)
- Cushing’s syndrome and adrenal insufficiency
Early and accurate differentiation between benign and malignant or functional and non-functional disease is essential for optimal management.
Importance of Specialized Care
Thyroid and adrenal diseases require precise diagnostic evaluation due to their complex hormonal and oncological nature.
In Germany, optimal care is based on multidisciplinary and precision-driven endocrine and oncologic assessment, which is central to INDID Telemedicine workflows.
Accurate hormonal profiling, high-resolution imaging, and cytological or histological confirmation are essential for treatment planning.
Within the INDID Telemedicine network, cases are evaluated in collaboration with endocrinologists, endocrine surgeons, nuclear medicine specialists, and oncologists through multidisciplinary tumor boards at certified partner centers in Germany.
Initial Diagnostic Workup and Risk Assessment
For most international patients, diagnostic evaluation can be initiated locally and completed in coordination with INDID Telemedicine without the need for immediate travel to Germany.
Baseline clinical assessment
- Medical and family history
- Physical examination (including neck and endocrine-related signs)
- Blood pressure assessment (especially in adrenal disease)
- Routine blood tests: full blood count, liver and renal function
Thyroid Evaluation
Laboratory testing
- TSH, free T3, free T4
- Thyroid antibodies (TPO, Tg antibodies)
- Calcitonin (if medullary thyroid cancer is suspected)
Imaging
- High-resolution neck ultrasound (first-line tool)
- CT or MRI (for locally advanced or invasive disease)
- Radioisotope scintigraphy (functional evaluation in selected cases)
- PET-CT (for aggressive or metastatic thyroid cancers)
Cytology and pathology
- Fine-needle aspiration biopsy (FNAB) is standard for thyroid nodules
- Bethesda classification is used for risk stratification
- Surgical pathology may be required for definitive diagnosis
All cytology and pathology reports are centrally reviewed. In selected cases, tissue slides or blocks may be reassessed in German reference pathology laboratories, particularly when diagnostic uncertainty exists.
Adrenal Evaluation
Hormonal assessment
- Cortisol (including dexamethasone suppression test)
- ACTH levels
- Aldosterone and renin ratio
- Plasma or urinary metanephrines (pheochromocytoma screening)
- Androgen profile (in suspected adrenal carcinoma)
Imaging
- CT adrenal protocol (first-line structural imaging)
- MRI adrenal (chemical shift imaging for lesion characterization)
- PET-CT in selected cases (malignancy assessment or metastasis detection)
High-quality imaging is essential for distinguishing benign adenomas from malignant or functional tumors.
Multidisciplinary Treatment Planning
All cases are reviewed in multidisciplinary endocrine and oncologic tumor boards at partner centers in Germany.
Treatment decisions are based on:
- Hormonal activity (functional vs non-functional tumors)
- Imaging characteristics
- Tumor size and growth dynamics
- Malignant potential
- Patient comorbidities and surgical risk
Treatment Modalities
Surgery
Surgical treatment is the cornerstone for many thyroid and adrenal diseases.
Thyroid surgery:
- Lobectomy or total thyroidectomy depending on tumor type and risk
- Central or lateral neck dissection in selected malignancies
Adrenal surgery:
- Laparoscopic adrenalectomy for benign lesions
- Open adrenalectomy for large or invasive tumors
- Organ-preserving approaches when feasible
Radioiodine Therapy (Thyroid)
- Standard adjuvant treatment for differentiated thyroid cancer
- Used for ablation of residual thyroid tissue and metastatic disease
Medical Therapy
- Thyroid hormone suppression therapy (TSH suppression)
- Antithyroid drugs for hyperthyroidism
- Steroid synthesis inhibitors for adrenal hyperfunction (e.g., Cushing’s syndrome)
- Alpha- and beta-blockade for pheochromocytoma preoperative preparation
Oncologic Systemic Therapy
For advanced or metastatic disease:
- Tyrosine kinase inhibitors (e.g., in radioactive iodine-refractory thyroid cancer)
- Targeted therapy based on molecular profiling
- Chemotherapy in selected aggressive adrenal cortical carcinoma cases
- Emerging immunotherapy approaches in clinical settings
Follow-Up Strategy
Follow-up is individualized based on disease type, functional status, and malignancy risk.
Typical follow-up schedule
- Every 3–6 months initially:
- Clinical assessment
- Hormonal laboratory tests (as applicable)
- Ultrasound (thyroid) or CT/MRI (adrenal)
- Long-term follow-up adjusted based on stability and recurrence risk
Telemedicine Follow-Up (INDID)
Patients treated in Germany generally do not require frequent travel for follow-up care.
INDID Telemedicine provides:
- Remote hormonal and imaging monitoring
- Specialist reassessment of recurrence or progression
- Coordination with local endocrinologists
- Long-term disease surveillance
Key Strength of INDID Telemedicine Approach
INDID Telemedicine integrates:
- Cross-border endocrine and oncologic diagnostic completion
- Centralized pathology and molecular review
- Multidisciplinary tumor board decision-making in Germany
- Personalized endocrine and surgical treatment planning
- Structured long-term remote hormonal and oncologic follow-up
This model ensures access to high-level German endocrine expertise while reducing delays in diagnosis and minimizing unnecessary international travel.
References
- Filetti, S., Durante, C., Hartl, D., et al. (2022). Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 33(12), 1290–1316. https://doi.org/10.1016/j.annonc.2022.09.010
- Fassnacht, M., Dekkers, O. M., Else, T., et al. (2020). European Society of Endocrinology Clinical Practice Guideline: Adrenocortical carcinoma. European Journal of Endocrinology, 183(1), G1–G34. https://doi.org/10.1530/EJE-20-0473
Lenders, J. W. M., et al. (2023). Pheochromocytoma and paraganglioma: diagnostic and management guidelines. Endocrine Reviews.
